Veradermics hair loss pill passes Phase 3 trial, could be first oral treatment approved in 30 years
Veradermics announced that its extended-release minoxidil tablet successfully met primary endpoints in a Phase 3 clinical trial for pattern hair loss. If approved by the FDA, it would become the first oral treatment for this condition authorized in the United States in approximately three decades. The drug is designed to be taken once daily and aims to offer a convenient alternative to topical minoxidil and other existing therapies. The company plans to submit a New Drug Application to the FDA in the coming months. The trial results were based on a study involving over 700 participants across multiple sites. Veradermics' stock price rose following the announcement.
Key facts
- Veradermics' extended-release minoxidil tablet passed a Phase 3 trial for pattern hair loss.
- The drug could be the first FDA-approved oral treatment for pattern hair loss in about 30 years.
- The trial involved over 700 participants across multiple sites.
- Veradermics plans to submit a New Drug Application to the FDA.
- The stock price of Veradermics rose after the announcement.
- The drug is taken once daily.
- It offers an alternative to topical minoxidil.
- The announcement was made in 2025.
Entities
Institutions
- Veradermics
- FDA
Locations
- United States
Sources
- Quartz —